Literature DB >> 19681975

Higher tacrolimus trough levels on days 2-5 post-renal transplant are associated with reduced rates of acute rejection.

C M O'Seaghdha1, R McQuillan, A M Moran, P Lavin, A Dorman, P O'Kelly, D M Mohan, P Little, D P Hickey, P J Conlon.   

Abstract

We analyzed the association between whole-blood trough tacrolimus (TAC) levels in the first days post-kidney transplant and acute cellular rejection (ACR) rates. Four hundred and sixty-four consecutive, deceased-donor kidney transplant recipients were included. All were treated with a combination of TAC, mycophenolate mofetil and prednisolone. Patients were analyzed in four groups based on quartiles of the mean TAC on days 2 and 5 post-transplant: Group 1: median TAC 11 ng/mL (n = 122, range 2-13.5 ng/mL), Group 2: median 17 ng/mL (n = 123, range 14-20 ng/mL), Group 3: median 24 ng/mL (n = 108, range 20.5-27 ng/mL) and Group 4: median 33.5 ng/mL (n = 116, range 27.5-77.5 ng/mL). A graded reduction in the rates of ACR was observed for each incremental days 2-5 TAC. The one-yr ACR rate was 24.03% (95% CI 17.26-32.88), 22.20% (95% CI 15.78-30.70), 13.41% (95% CI 8.15-21.63) and 8.69% (95% CI 4.77-15.55) for Groups 1-4, respectively (p = 0.003). This study suggests that higher early TACs are associated with reduced rates of ACR at one yr.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681975     DOI: 10.1111/j.1399-0012.2009.01021.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  14 in total

1.  PharmGKB summary: very important pharmacogene information for CYP3A5.

Authors:  Jatinder Lamba; Joan M Hebert; Erin G Schuetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-07       Impact factor: 2.089

2.  Dosing equation for tacrolimus using genetic variants and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; William S Oetting; Ajay K Israni; Pamala A Jacobson
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.

Authors:  Megan V Yanik; Michael E Seifert; Jayme E Locke; Vera Hauptfeld-Dolejsek; Michael R Crowley; Gary R Cutter; Roslyn B Mannon; Daniel I Feig; Nita A Limdi
Journal:  Pediatr Transplant       Date:  2019-05-24

4.  The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.

Authors:  P Stratta; M Quaglia; T Cena; R Antoniotti; R Fenoglio; A Menegotto; D Ferrante; A Genazzani; S Terrazzino; C Magnani
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

5.  Clinical efficacy and pharmacokinetics of tacrolimus in children with steroid-resistant nephrotic syndrome.

Authors:  Afsana Jahan; Ratna Prabha; Swasti Chaturvedi; Binu Mathew; Denise Fleming; Indira Agarwal
Journal:  Pediatr Nephrol       Date:  2015-07-02       Impact factor: 3.714

6.  Validation of tacrolimus equation to predict troughs using genetic and clinical factors.

Authors:  Chaitali Passey; Angela K Birnbaum; Richard C Brundage; David P Schladt; William S Oetting; Robert E Leduc; Ajay K Israni; Weihua Guan; Arthur J Matas; Pamala A Jacobson
Journal:  Pharmacogenomics       Date:  2012-07       Impact factor: 2.533

Review 7.  A Systematic Literature Review Approach to Estimate the Therapeutic Index of Selected Immunosuppressant Drugs After Renal Transplantation.

Authors:  Jessica E Ericson; Kanecia O Zimmerman; Daniel Gonzalez; Chiara Melloni; Jeffrey T Guptill; Kevin D Hill; Huali Wu; Michael Cohen-Wolkowiez
Journal:  Ther Drug Monit       Date:  2017-02       Impact factor: 3.118

8.  Genetic polymorphisms of pharmacogenomic VIP variants in the Uygur population from northwestern China.

Authors:  Li Wang; Ainiwaer Aikemu; Ayiguli Yibulayin; Shuli Du; Tingting Geng; Bo Wang; Yuan Zhang; Tianbo Jin; Jie Yang
Journal:  BMC Genet       Date:  2015-06-20       Impact factor: 2.797

9.  A 12-month single arm pilot study to evaluate the efficacy and safety of sirolimus in combination with tacrolimus in kidney transplant recipients at high immunologic risk.

Authors:  Juhan Lee; Jung Jun Lee; Beom Seok Kim; Jae Geun Lee; Kyu Ha Huh; Yongjung Park; Yu Seun Kim
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153

10.  Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.

Authors:  Takenori Niioka; Hideaki Kagaya; Mitsuru Saito; Takamitsu Inoue; Kazuyuki Numakura; Tomonori Habuchi; Shigeru Satoh; Masatomo Miura
Journal:  Int J Mol Sci       Date:  2015-01-14       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.